Peptide-targeted PEG-liposomes in anti-angiogenic therapy

被引:67
作者
Janssen, APCA
Schiffelers, RM
ten Hagen, TLM
Koning, GA
Schraa, AJ
Kok, RJ
Storm, G [1 ]
Molema, G
机构
[1] UIPS, Dept Pharmaceut, Utrecht, Netherlands
[2] Univ Rotterdam Hosp, Dept Expt Surg Oncol, Daniel Hoed Canc Ctr, Rotterdam, Netherlands
[3] Univ Groningen, Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, Groningen, Netherlands
关键词
angiogenesis; RGD-peptides; liposomes; endothelial cells;
D O I
10.1016/S0378-5173(02)00682-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peptides with the RGD amino acid sequence show affinity for the alpha(v)beta(3) integrin, an integrin which is over-expressed on angiogenic endothelium and involved in cell adhesion. A peptide with the sequence ATWLPPR has been demonstrated to show affinity for the vascular endothelial growth factor (VEGF) receptor, a receptor involved in the proliferation of endothelial cells. By coupling these peptides to liposomes, these liposomes can serve as a site-specific drug delivery system to tumor endothelial cells in order to inhibit angiogenesis. In the present study we demonstrate that the coupling of cyclic RGD-peptides or ATWLPPR-peptides to the surface of PEG-liposomes results in binding of these liposomes to endothelial cells in vitro. Subsequent studies with RGD-peptide targeted liposomes in vivo also demonstrate specific binding to the tumor endothelium. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:55 / 58
页数:4
相关论文
共 8 条
[1]   Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis [J].
Binétruy-Tournaire, R ;
Demangel, C ;
Malavaud, B ;
Vassy, R ;
Rouyre, S ;
Kraemer, M ;
Plouët, J ;
Derbin, C ;
Perret, G ;
Mazie, JC .
EMBO JOURNAL, 2000, 19 (07) :1525-1533
[2]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[3]  
DRAKE CJ, 1995, J CELL SCI, V108, P2655
[4]   The role of αv integrins during angiogenesis:: insights into potential mechanisms of action and clinical development [J].
Eliceiri, BP ;
Cheresh, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1227-1230
[5]  
Griffioen AW, 2000, PHARMACOL REV, V52, P237
[6]   TRANSPARENT ACCESS CHAMBER FOR THE RAT DORSAL SKIN FOLD [J].
PAPENFUSS, HD ;
GROSS, JF ;
INTAGLIETTA, M ;
TREESE, FA .
MICROVASCULAR RESEARCH, 1979, 18 (03) :311-318
[7]   RGD and other recognition sequences for integrins [J].
Ruoslahti, E .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1996, 12 :697-715
[8]   Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): Optimization of prodrug activating capacity [J].
Vingerhoeds, MH ;
Haisma, HJ ;
Belliot, SO ;
Smit, RHP ;
Crommelin, DJA ;
Storm, G .
PHARMACEUTICAL RESEARCH, 1996, 13 (04) :604-610